Bo Kruse - Jan 17, 2023 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
EVP, CFO, Secry & Treas.
Signature
/s/ Bo Kruse
Stock symbol
YMAB
Transactions as of
Jan 17, 2023
Transactions value $
$0
Form type
4
Date filed
1/19/2023, 03:34 PM
Previous filing
Apr 28, 2022
Next filing
Jan 22, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Award $0 +11.7K +6.46% $0.00 193K Jan 17, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Employee Stock Option (right to buy) Award $0 +70.1K $0.00 70.1K Jan 17, 2023 Common Stock 70.1K $4.70 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 11,700 restricted stock units ("RSUs") granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU. The RSUs vest by 1/3 on each of January 17, 2024, January 17, 2025 and January 17, 2026 subject to the continuing employment of the Reporting Person on each vesting date.
F2 Stock options granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.
F3 The stock options shall vest and become exercisable as to 25% of the shares subject to the option on January 17, 2024, and thereafter vests and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.